p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway

(2010) Tetsuya Kurosu et al.   APOPTOSIS

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA

(2010) Carolyn Y. Zhao et al.   CELL CYCLE

p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation

(2010) M Xia et al.   ONCOGENE

HIPK2 Regulation by MDM2 Determines Tumor Cell Response to the p53-Reactivating Drugs Nutlin-3 and RITA

(2009) C. Rinaldo et al.   CANCER RESEARCH

Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors

(2009) S. Romeo et al.   CLINICAL CANCER RESEARCH

Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1  and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia

(2009) J. Yang et al.   MOLECULAR AND CELLULAR BIOLOGY

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

(2008) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY